title: Uremic Itch Management.
abstract: Uremic itch is a frequent and sometimes very tormenting symptom in patients with advanced or end-stage renal failure, with a strong negative impact on the quality of life. According to a representative study, the point prevalence of chronic itch is 25% in hemodialysis patients but may reach more than 50% in single cohorts depending on the country and dialysis efficacy. Not much is known regarding the pathogenesis of uremic itch. Besides parathyroid hormone, histamine, tryptase, and alteration of the calcium-phosphate metabolism have been suspected. More recently, derangements in the opioid system and an inflammatory condition have been investigated as suspected players in the pathogenesis of uremic itch, but remain unproven so far. Treatment of chronic itch in dialysis patients remains difficult. Besides topical application of rehydrating or immunomodulating compounds, such as γ-linolenic acid or tacrolimus treatment with nalfurafine may be helpful. Apart from that, gabapentin and pregabalin are promising drugs to alleviate uremic itch. In many cases, UVB phototherapy is effective in reducing the intensity of itch. When treating patients, one should take into account that most of the drugs available are not licensed for the treatment of itch. Therefore, a deliberate use of therapeutic options aiming for a good risk-benefit relation should be adopted. In very severe and refractory cases, patients suitable for renal transplantation might be switched to 'high urgency' status, as successful renal transplantation cures uremic pruritus in most of the cases.
authors: DKD Helios Klinik, Wiesbaden, Germany.
authors: Thomas
authors: T
authors: Mettang
mesh_terms: D015670:Acupuncture Therapy; D000588:Amines / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D065095:Calcineurin Inhibitors / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D009019:Morphinans / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D000069583:Pregabalin / Q000627:therapeutic use; D011537:Pruritus / Q000209:etiology / Q000628:therapy*; D017473:Receptors, Opioid, kappa / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D006435:Renal Dialysis; D013141:Spiro Compounds / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014511:Uremia / Q000150:complications / Q000628:therapy*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use; D017965:gamma-Linolenic Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000701:Analgesics, Opioid; D000927:Anticonvulsants; D065095:Calcineurin Inhibitors; D003509:Cyclohexanecarboxylic Acids; D009019:Morphinans; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D013141:Spiro Compounds; C111212:TRK 820; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D017965:gamma-Linolenic Acid; D016559:Tacrolimus